scholarly journals Treating Postprandial Hyperglycemia Does Not Appear to Delay Progression of Early Type 2 Diabetes: The Early Diabetes Intervention Program

Diabetes Care ◽  
2006 ◽  
Vol 29 (9) ◽  
pp. 2095-2101 ◽  
Author(s):  
M. S. Kirkman ◽  
R. R. Shankar ◽  
S. Shankar ◽  
C. Shen ◽  
E. Brizendine ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Intervention Program ◽  
Postprandial Hyperglycemia ◽  
Early Type ◽  
Early Diabetes ◽  
Diabetes Intervention ◽  
Delay Progression

scholarly journals Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus

2010 ◽  
Vol 8 (4) ◽  
pp. 828-837 ◽  
Author(s):  
F. SANTILLI ◽  
G. FORMOSO ◽  
P. SBRACCIA ◽  
M. AVERNA ◽  
R. MICCOLI ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Platelet Activation ◽  
Postprandial Hyperglycemia ◽  
Early Type

1561-P: Associations between ß-Cell Function and Cognitive Measures Differ in Youth vs. Adults with Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes (T2D)

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1561-P
Author(s):  
SUZANNE CRAFT ◽  
AMY CLAXTON ◽  
MARK TRIPPUTI ◽  
SHARON EDELSTEIN ◽  
SILVA A. ARSLANIAN ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Cell Function ◽  
Early Type ◽  
Cognitive Measures

Developing a Health Economic Model for Asians with Type 2 Diabetes Based on the Japan Diabetes Complications Study and the Japanese Elderly Diabetes Intervention Trial

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2319-PUB
Author(s):  
SHIRO TANAKA ◽  
JAKOB LANGER ◽  
TIM MORTON ◽  
LARS WILKINSON ◽  
SACHIKO TANAKA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Health Economic ◽  
Economic Model ◽  
Diabetes Complications ◽  
Intervention Trial ◽  
Health Economic Model ◽  
Japanese Elderly ◽  
Diabetes Intervention

Diabetes Remission Clinical Trial (DiRECT)—Plasma Liver Function Tests Reflect Change in Liver Fat Content in Early Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1834-P
Author(s):  
SVIATLANA V. ZHYZHNEUSKAYA ◽  
AHMAD AL-MRABEH ◽  
CARL PETERS ◽  
ALISON C. BARNES ◽  
KIEREN G. HOLLINGSWORTH ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Liver Function ◽  
Liver Function Tests ◽  
Fat Content ◽  
Diabetes Remission ◽  
Liver Fat ◽  
Early Type ◽  
Liver Fat Content

Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update

2019 ◽  
Vol 25 (23) ◽  
pp. 2510-2525 ◽  
Author(s):  
Bashir Usman ◽  
Neha Sharma ◽  
Saurabh Satija ◽  
Meenu Mehta ◽  
Manish Vyas ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Patient Compliance ◽  
Postprandial Hyperglycemia ◽  
Diabetic Patients ◽  
Poor Patient ◽  
Glucosidase Inhibitors ◽  
Poor Patient Compliance ◽  
Recent Developments ◽  
Alpha Glucosidase

The incidence of diabetes has increased globally in recent years and figures of diabetic patients were estimated to rise up to 642 million by 2040. The disorder is accompanied with various complications if not managed at the early stages, and interlinked high mortality rate and morbidity with time. Different classes of drugs are available for the management of type 2 diabetes but were having certain limitations of their safety. Alphaglucosidase is a family of enzyme originated from the pancreas which plays a role in the anabolism of 80-90% of carbohydrate consumed into glucose. This glucose is absorbed into the blood and results in frank postprandial hyperglycemia and worsens the conditions of diabetic patients which precipitate complications. Inhibition of these enzymes helps to prevent postprandial hyperglycemia and the formation of glycated end products. Alphaglucosidase inhibitors are reported to be more important in adequate control of type 2, but marketed drugs have various side effects, such as poor patient compliance and also expensive. This proves the needs for other class of drugs with better efficacy, safety, patient compliance and economic. In this review, we have emphasized the recent advances in the field of new alpha-glucosidase inhibitors with improved safety and pharmacological profile.

Sign in / Sign up

Export Citation Format

Share Document